Market Overview

H.C. Wainwright Talks Kamada's Recent Phase 2 Results


Kamada Ltd (NASDAQ: KMDA) reported positive topline results from its Phase 2 biomarker study of inhaled alpha-1 [AAT-IH] for the treatment of alpha-1 antitrypsin deficiency [AATD]. H.C. Wainwright’s Andrew S. Fein maintained a Buy rating on the company, with a price target of $10.

The Phase 2 study of AAT-IH in AATD patients demonstrated “a significant increase in endothelial lining fluid (ELF) AAT antigenic level compared to the placebo group,” analyst Fein mentioned.

3 Objectives Met

Fein commented that although this was not a registrational study, the positive results achieve three important objectives for the long-run realization of value for AAT-IH.

  • Objective 1: Fein commented that the first objective accomplished was gaining “incremental proof” that AAT has efficacy in inhalation formulation.
  • Objective 2: Kamada is currently compiling responses to the EMA’s 120-day of questioning, and the Phase 2 results provide more data that can be submitted to the EMA.
  • Objective 3: Kamada is also in ongoing discussions with the FDA and the Phase 2 readout is a step closer to “solidifying a registrational trial design with an approvable clinically meaningful endpoint,” which is expected to be another key catalyst for the company’s stock, the analyst stated.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for KMDA

Feb 2018Initiates Coverage OnBuy
Nov 2015MaintainsBuy
Jun 2013Initiates Coverage onOutperform

View More Analyst Ratings for KMDA
View the Latest Analyst Ratings

Posted-In: Andrew S. Fein H.C. WainwrightAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas


Related Articles (KMDA)

View Comments and Join the Discussion!

Lean Hog Futures Little Higher

Apple's EU Tax Bill 'Shows The Wisdom Of Brexit'